

DATE:	24 April 2024
TO:	Oncologists, Province Wide
FROM:	Edmonton Zone Immunohistochemistry Laboratory, Alberta Precision Laboratories (APL)
RE:	Request for Additional Testing for Pathology Samples- PD-L1 Biomarker Ordering

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Ordering of PD-L1 biomarker immunohistochemistry (IHC) testing in Epic through the Request for Additional Testing for Pathology Sample pathway will be changing and expect regular updates as testing for eligibility to immunotherapy evolves constantly.
- Please be aware that each PDL1 report fits the purpose of immunotherapy eligibility for a specific drug and a specific disease as explained in the disclaimer of each individual report.
- The selection fields for PD-L1 will be changed to reflect the diagnostic testing assay and drug therapy offered in Alberta.

Background

- Specific drug therapies require a specific diagnostic test assay to determine eligibility for treatment with that drug; these assays cannot be interchanged to determine different drug therapy eligibilities.
- Previously, the ordering fields included drop down menus which allowed the ordering oncologist the option to choose the disease, drug therapy and diagnostic test. This led to orders being placed for diagnostic test and drug therapy combinations which are not currently offered in Alberta.
- The selection fields now include the combination of disease, drug therapy and diagnostic test which are currently offered in Alberta.

Action Required

For all PD-L1 testing except for Lung NSCLC- Non-squamous (Adenocarcinoma)

- **In Epic:** Use “Request for Additional Testing for Pathology Samples”
- **Select:**
 - Requested Test: PD-L1
 - PD-L1 Testing: Select PD-L1 based on disease and drug therapy



Requested Tests	PD-L1	Comments
		Comments
PD-L1 Testing	Breast Triple Negative - Pembrolizumab - 22C3	
	Head and Neck Squamous Cell Carcinoma - Pembrolizumab - 22C3	
	Lung NSCLC - Pembrolizumab - 22C3 - Advanced Stage	
	Lung NSCLS - Atezolizumab - SP263 - Early Stage	
	Upper GI - Nivolumab - 28-8	
	Uterine Cervix - SCC and Adenocarcinoma - Pembrolizumab - 22C3	
	Other (specify in comment box to the right)	
Surgical Case #:		

For all Lung NSCLC- Non-squamous (Adenocarcinoma) PD-L1 testing

- **In Epic:** Use “Request for Additional Testing for Pathology Samples”
- **Select:**
 - Requested Test: Lung Carcinoma Mutation Analysis (MP-C,E)
 - Staging: Select based on staging and drug therapy

Requested Tests	Lung Carcinoma Mutation Analysis (MP-C,E)	
Staging:	Lung NSCLC-Pembrolizumab -22C3 (Stages IIIB/IV)	
	Lung NSCLC- Atezolizumab - SP263 (Adjuvant therapy Stages II/IIIA)	

Effective April 25, 2024

Questions/Concerns

Edmonton:

- **IHC:** Dr. Gilbert Bigras-Director IHC Laboratory, Gilbert.Bigras@albertaprecisionlabs.ca 780-432-8445

Calgary:

- **IHC:** Paul Klonowski – Associate Medical Director; Director IHC Laboratory, Calgary 403-770-3430

Approved by

- Dr. Carolyn O’Hara, Interim Chief Medical Laboratory Officer, Alberta Precision Laboratories

Effective September 1, 2023, APL has become the sole provider of all public lab services in Alberta. As a result, community lab services formally provided by DynaLIFE Medical Labs will become the responsibility of Alberta Precision Labs (APL). This change impacts all zones.